Epirubicin: a phase II study in recurrent small-cell lung cancer

Mark Rosenthal, Richard Kefford, Derek Raghavan, Robin Stuart-Harris*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Epirubicin (4′-epidoxorubicin), an analogue of doxorubicin (Adriamycin), has established activity in the treatment of small-cell lung cancer (SCLC) when used at doses of 75 to 120 mg/m2 in previously untreated patients. We completed a phase II study of epirubicin (85 mg/m2 given intravenously at 3-week intervals) in 20 patients with recurrent SCLC, all of whom had received prior combination chemotherapy. Of 19 patients who were assessable for response, 2 achieved a complete response and 2 a partial response, for an overall response rate of 4/19 (21%); 95% confidence interval, 8%-43%). Myelosuppression and alopecia were the most frequent toxicities; epirubicin was otherwise well tolerated, with other toxicities such as nausea and vomiting being infrequent or mild. Epirubicin at a dose of 85 mg/m2 exhibits modest singleagent activity in previously treated SCLC and is generally well tolerated. Given as a single agent or in combination with other well-tolerated drugs, epirubicin would be suitable in cases in which palliation of symptoms without undue toxicity is required in the management of previously treated SCLC.

Original languageEnglish
Pages (from-to)220-222
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Issue number3
Publication statusPublished - May 1991
Externally publishedYes


Dive into the research topics of 'Epirubicin: a phase II study in recurrent small-cell lung cancer'. Together they form a unique fingerprint.

Cite this